{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.3","spread":"32.3","upperLimit":"60.4","value":"46.2"},{"groupId":"OG001","lowerLimit":"35.1","spread":"35.1","upperLimit":"62.6","value":"48.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Percentage of participants achieving VGPR or better response were reported. VGPR or better rate was defined as the percentage of participants achieving VGPR, complete response (CR), or stringent complete response (sCR) in accordance with the International Myeloma Working Group (IMWG) criteria, during or after the study treatment but before the start of subsequent anti-myeloma therapy. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or greater than or equal to (\\>=) 90 percent (%) reduction in serum M-protein plus urine M-protein less than (\\<) 100 milligram (mg)/24 hours; for CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas (PCs), and \\<5% PCs in bone marrow; for sCR: CR plus normal free light chain (FLC) ratio, and Absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4- color flow cytometry.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received carfilzomib 20 milligram per meter square (mg/m\\^2) intravenously (IV) on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and thereafter on Days 1, 8, 15 from Cycle 2 onwards. Participants received dexamethasone 20 milligrams (mg) on Cycle 1 Days 1 and 2, and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed progressive disease (PD), death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG000","title":"Arm A: Carfilzomib+Dexamethasone (Kd)"},{"description":"Participants received daratumumab 1800 mg by SC injection (Dara-SC) on Days 1, 8, 15, 22 of Cycle 1 and 2, Days 1 and 15 of Cycle 3-6, and on Day 1 from Cycle 7 onwards. Participants received carfilzomib 20 mg/m\\^2 IV on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and Days 1, 8 and 15 from Cycle 2 onwards. Participants received dexamethasone 20 mg on Cycle 1 Days 1 and 2 and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed PD, death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG001","title":"Arm B: Dara-SC in Combination With Kd (DKd)"}],"paramType":"NUMBER","populationDescription":"The response-evaluable analysis set included participants who had confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 4 months","title":"Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}